Erdafitinib
About
Therapy type: Targeted therapy
Therapy strategy: FGFR inhibition
Mappings
NCI Thesaurus: Erdafitinib (ncit:C103273)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (1) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | FGFR2::BICC1 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | FGFR2::CASP7 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | FGFR3::BAIAP2L1 | Bladder Urothelial Carcinoma | Erdafitinib |